Differential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes

British Journal of Haematology

Volumn 131, Issue 3, 2005, Pages 313-319

  Porakishvili, N ^a,b   Kulikova, N ^a   Jewell, A P ^c   Youinou, P Y ^d   Yong, K ^e   Nathwani, A ^e   Heelan, B ^a   Duke, V ^e   Hamblin, T J ^f   Wallace, P ^g   Ely, P ^g   Clark, E A ^h   Lydyard, P M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

^c KINGSTON UNIVERSITY   (United Kingdom)

^d UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

B cell chronic lymphocytic leukaemia; CD180; IGVH mutation; Toll like receptor

Indexed keywords

CD180 PROTEIN; IMMUNOGLOBULIN M; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; CD180 PROTEIN, HUMAN; IMMUNOGLOBULIN HEAVY CHAIN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD; CLINICAL TRIAL; GENETICS; IMMUNOGLOBULIN GENE; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; MULTICENTER STUDY; MUTATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN M; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL, CHRONIC; MIDDLE AGED; MUTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 33644800269     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05775.x     Document Type: Article

References (29)

1. Damle R.N. Wasil T. Fais F. Ghiotto F. Valetto A. Allen S.L. Buchbinder A. Budman D. Dittmar K. Kolitz J. Lichtman S.M. Schulman P. Vinciguerra V.P. Rai K.R. Ferrarini M. Chiorazzi N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, 1840 1847.
2. Damle R.N. Ghiotto F. Valetto A. Albesiano E. Fais F. Yan X.-J. Sison C.P. Allen S.L. Kolitz J. Schulman P. Vinciguerra V.P. Budde P. Frey J. Rai K.R. Ferrarini M. Chiorazzi N. (2002) B-cell chronic lymphocytic leukaemia cells express a surface membrane phenotype of activated, antigen experienced B lymphocytes. Blood, 99, 4087 4093.
3. Ghia P. Guida G. Stella S. Gottardi D. Geuna M. Strola G. Scielzo C. Caligaris-Cappio F. (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood, 101, 1262 1269.
4. Guyre P.M. Graziano R.F. Vance B.A. Morganelli P.M. Fanger M.W. (1989) Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. Journal of Immunology, 143, 1650 1655.
5. Hamblin T.J. Davis Z. Gardiner A. Oscier D.G. Stevenson F.K. (1999) Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukaemia. Blood, 94, 1848 1854.
6. Hamblin T.J. Orchard J.A. Ibbotson R.E. Davis Z. Thomas P.W. Stevenson F.K. Oscier D.G. (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood, 99, 1023 1029.
7. Huhn D. von Schilling C. Wilhelm M. Ho A.D. Hallek M. Kuse R. Knauf W. Riedel U. Hinke A. Srock S. Serke S. Peschel C. Emmerich B. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood, 98, 1326 1331.
8. Kadowaki N. Ho S. Antonenko S. de Waal Malefyt R. Kastelein R.A. Bazan F. Yong-Jun L. (2001) Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. Journal of Experimental Medicine, 194, 863 870.
9. Kim S.Z. Chow K.U. Kukoc-Zivojnov N. Boehrer S. Brieger A. Steimle-Grauer S.A. Harder L. Hoelzer D. Mitrou P.S. Weidmann E. (2004) Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leukaemia and Lymphoma, 45, 2037 2045.
10. Klein U. Tu Y. Stolovitsky G.A. Mattiola M. Cattoretti G. Husson H. Freedman A. Inghirami G. Cro L. Baldini L. Neri A. Califano A. Dalla-Favera R. (2001) Gene expression profiling of B cell chronic lymphocytic leukaemia reveals a homogeneous phenotype related to memory B cells. Journal of Experimental Medicine, 194, 1625 1638.
11. Koarada S. Tada Y. Ushiyama O. Morito F. Suzuki N. Ohta A. Miyake K. Kimoto M. Nagasawa K. (1999) B cells lacking RP105, a novel cell antigen, in systemic lupus erythematosus. Arthritis and Rheumatism, 42, 2593 2600.
12. Koarada S. Tada Y. Kikuchi Y. Ushiyama O. Suzuki N. Ohta A. Nagasawa K. (2001) CD180 (RP105) in rheumatic diseases. Rheumatology, 40, 1315 1316.
13. Lanham S. Hamblin T. Oscier D. Ibbotson R. Stevenson F.K. Packham G. (2002) Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukaemia. Blood, 101, 1087 1093.
14. Mainou-Fowler T. Dignum H. Taylor P.R. Dickinson A.M. Saunders P.W.G. Proctor S.J. Summerfield G.P. (2002) Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 118, 755 761 Kimoto M. (1998) RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood, 92, 2815 2822.
15. Miyake K. Yamashita Y. Ogata M. Sudo T. Kimoto M. (1995) RP105, a novel B cell surface molecule implicated in B cells activation is a member of the leucine-rich repeat protein family. Journal of Immunology, 154, 3333 3340.
16. Miyake K. Shimazu R. Kondo J. Niki T. Akashi S. Ogata H. Yamashita Y. Miura Y. Kimoto M. (1998) Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. Journal of Immunology, 161, 1348 1353.
17. Moller P. Mielke B. (1989) Extensive analysis of tissue distribution of antigens defined by new clustered and unclustered B-cell antibodies, B22.4. In: Leucocyte Typing IV (ed. by W. Knapp B. Dorkien W.R. Gilks E.P. Reiber R.E. Schmidt H. Stein Kr. A.E.G. Von dern Borne pp. 175 177. Oxford University Press, Vienna.
18. H- proximal variable gene segments. Blood, 97, 2716 2726.
19. Otipoby K.L. Nagai Y. Shu G.L. Miyake K. Clark E.A. (2002) CD180 (RP105/Bgp95) workshop report. In: Leukocyte Typing VII. White Cell Differentiation Antigens (ed. by D.Y. Mason pp. 120 123. Oxford University Press, Oxford Jamin C. (2002) CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. Leukemia, 16, 44 52.
20. Porakishvili N. Kulikova N. Manoussaka M. Jewell A.P. Youinou P.Y. Nedelec S. Yong K. Nathwani A. Heelan B. Hamblin T. Wallace P. Ely P. Clarke E. Lydyard P.M. (2004) Differential expression of CD180 and sIgM by B chronic lymphocytic leukaemia (B-CLL) using mutated and unmutated IgVh genes. Blood, 104, 768a (abstract).
21. Roshak A.K. Anderson K.M. Holmes S.D. Jonak Z. Bolognese B. Terrett J. Marshall L.A. (1999) Anti-human RP105 sera induces lymphocyte proliferation. Journal of Leukocyte Biology, 65, 43 49.
22. Schnare M. Barton G.M. Czopik Holt A. Takeda K. Akira S. Medzhitov R. (2001) Toll-like receptors control activation of adaptive immune responses. Nature Immunology, 2, 947 950.
23. Thompson A.A. Talley J.A. Do H.N. Kagan H.L. Kunkel L. Berenson J. Cooper M.D. Saxon A. Wall R. (1997) Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood, 90, 1387 1394.
24. Valentine M.A. Clarke E.A. Shu G.L. Norris N.A. Ledbetter J.A. (1988) Antibody to a novel 95-kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. Journal of Immunology, 140, 4071 4078.
25. Wiestner A. Rosenwald A. Barry T.S. Wright G. Davis R.E. Henrickson S.E. Zhao H. Ibbotson R.E. Orchard J.A. Davis Z. Steler-Stevenson M. Raffeld M. Arthur D.C. Marti G.E. Wilson W.H. Hamblin T.J. Oscier D.G. Staudt L.M. (2003) ZAP-70 expression identifies a chronic lymphocytic leukaemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood, 101, 4944 4951.
26. Yamashita Y. Miyake K. Miura Y. Kaneko Y. Yagita H. Suda T. Nagata S. Nomura J. Sakaguchi N. Kimoto M. (1996) Activation mediated by RP105 but not CD40 makes normal B cells susceptible to anti-IgM-induced apoptosis: a role for Fc receptor coligation. Journal of Experimental Medicine, 184, 113 120.
27. Yazawa N. Fujimoto M. Sato S. Miyake K. Asano N. Nagai Y. Takeuchi O. Takeda K. Okochi H. Akira S. Tedder T.F. Tamaki K. (2003) CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood, 102, 1374 1380.
28. Zerember K.A. Godowski P.J. (2002) Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocyte responses to microbes, their products and cytokines. Journal of Immunology, 168, 554 561.
29. Zupo S. Isnardi L. Megna M. Massara R. Malvasi F. Dono M. Cosulich E. Ferrarini M. (1996) CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood, 88, 1365 1374.